About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration, with Radial Health, Inc., a growing national network of interventional psychiatry practices leveraging technology and operations expertise to optimize models of care delivery. This collaboration will further help to inform the development of scalable de ...

Core Insights - The training course titled "The Applications of Nanoparticles in the Pharmaceutical and Biomedical Industries" is scheduled for March 11th - 12th, 2026, and aims to provide an in-depth understanding of nanoparticle technology and its applications in these industries [1][2]. Industry Overview - Nanoparticles are increasingly recognized for their ability to interact with biological systems at the molecular level, making them valuable in drug delivery, diagnostics, and therapeutic innovations [3]. - The course will cover various types of nanoparticles, including liposomes, polymeric nanoparticles, and metallic nanoparticles, and their specific applications in pharmaceutical, medtech, and biotech industries [4]. Course Content - Key topics include: - Overview of nanotechnology and its significance in pharmaceuticals and biomedicine [7]. - Characterization of nanoparticles, including size, shape, and surface properties [8]. - Applications of nanoparticles in drug delivery, diagnostics, imaging, and cancer therapy [11]. - Regulatory and safety considerations for nanoparticle-based pharmaceuticals [11]. - Future trends and innovations in nanoparticle research and development [12]. Target Audience - The course is designed for a diverse group of professionals, including pharmaceutical scientists, biomedical engineers, drug development professionals, regulatory affairs specialists, and clinical researchers [6]. Expert Insights - The course will be led by Mohammed Alkattan, who has extensive experience in the development of nanoparticles for drug delivery and clinical applications [12][13].

Cytokinetics, Incorporated (NASDAQ:CYTK) is a prominent biopharmaceutical company dedicated to the development of innovative treatments based on muscle biology for serious diseases such as heart failure and amyotrophic lateral sclerosis (ALS). Competing in the dynamic biotech industry against giants like Amgen and Biogen, Cytokinetics has recently been in the spotlight due to significant insider trading activity by its Executive Vice President, Andrew Callos.On January 5, 2026, Andrew Callos executed a nota ...

Core Insights - Arcus Biosciences reported significant insider selling by President Juan C. Jaen, who sold 82,997 shares for approximately $2.1 million, coinciding with a strong one-year stock performance [1][2][9] - The sale represented 5.91% of Jaen's total holdings and 8.00% of his indirect holdings, which is above the historical median of 4.67% for recent transactions [3] - The company has a market capitalization of $2.7 billion and a revenue of $240 million, with a one-year price change of 45% as of January 5, 2026 [4] Transaction Details - The shares were sold at a weighted average price of $24.71, while the stock closed at $25.26 on the transaction date, reflecting a 47.68% total return over the past year [6][10] - The transaction was executed through an indirect holding via a trust, with no change to direct holdings [6] - Since June 2024, Jaen's holdings have decreased by 76.39%, indicating a larger-than-typical disposition relative to prior activity [6] Company Overview - Arcus Biosciences focuses on developing oncology therapies, including several candidates in Phase 1-3 clinical trials, such as Etrumadenant and Zimberelimab [7][8] - The company targets cancers like non-small cell lung cancer and pancreatic cancer, leveraging strategic partnerships for clinical development [8] - Despite a recent setback in a Phase 3 trial, Arcus maintains a strong balance sheet with approximately $1 billion in cash and promising early-stage results for its kidney cancer program [11]

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to two new employees under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted non-qualified stock options to purchase 1,000,000 shares o ...

– Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00AM ET on January 6, 2026, to report topline results for the Phase 2 trial of BMB-101 in patients with drug-r ...

Key Takeaways KYMR surged after KT-621 showed deep STAT6 degradation and strong EASI and pruritus reductions.KT-621 cut multiple type 2 biomarkers and was mostly safe, supporting its potential as a once-daily therapy.FDA Fast Track and ongoing phase IIb AD and asthma studies position KT-621 for broader late-stage development.Kymera Therapeutics, Inc. (KYMR) has put up a stupendous performance over the past year. Shares of this clinical-stage biotechnology company have surged 82.4% over the said time frame c ...

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Market update : Stocks are higher for the second session in a row. Energy is a big story on Monday, with oilfield services, refiners, and the two majors, Exxon Mobil and Chevron , rallying on the idea that they will be beneficiaries of the rebuilding of Venezuela's oil infrastructure following the events over the weekend. The financials a ...

VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 Labs, Inc. (OTC:FITY) today issues the following clarification regarding its press release dated August 26, 2025, which referenced a potential collaboration with LUNR Aerospace. It is the intent of this press release to clarify and confirm that no formal partnership or collaboration has ever been formed between Fifty1 Labs, Inc. (or its subsidiary Fifty1 AI Labs) and LUNR Aerospace and there is no current intent to do so. Mr. A ...